共 50 条
Gut hormones: the future of obesity treatment?
被引:21
|作者:
McGavigan, Anne K.
[1
]
Murphy, Kevin G.
[1
]
机构:
[1] Univ London Imperial Coll Sci Technol & Med, Dept Invest Med, Sect Invest Med, London W12 0NN, England
基金:
英国生物技术与生命科学研究理事会;
关键词:
glucagon-like peptide-1;
gut hormones;
obesity;
oxyntomodulin;
pancreatic polypeptide;
peptide YY;
GLUCAGON-LIKE PEPTIDE-1;
INHIBITS FOOD-INTAKE;
REDUCES BODY-WEIGHT;
PROOF-OF-CONCEPT;
PANCREATIC-POLYPEPTIDE;
RECEPTOR AGONISTS;
INTRAVENOUS-INFUSION;
ENERGY-INTAKE;
IN-VITRO;
OXYNTOMODULIN;
D O I:
10.1111/j.1365-2125.2012.04278.x
中图分类号:
R9 [药学];
学科分类号:
1007 ;
摘要:
Obesity is a major worldwide health problem. The treatment options are severely limited. The development of novel anti-obesity drugs is fraught with efficacy and safety issues. Consequently, several investigational anti-obesity drugs have failed to gain marketing approval in recent years. Anorectic gut hormones offer a potentially safe and viable option for the treatment of obesity. The prospective utility of gut hormones has improved drastically in recent years with the development of longer acting analogues. Additionally, specific combinations of gut hormones have been demonstrated to have additive anorectic effects. This article reviews the current stage of anti-obesity drugs in development, focusing on gut hormone-based therapies.
引用
收藏
页码:911 / 919
页数:9
相关论文